![Joseph A. Markey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph A. Markey
Plus aucun poste en cours
Historique de carrière de Joseph A. Markey
Anciens postes connus de Joseph A. Markey
Sociétés | Poste | Début | Fin |
---|---|---|---|
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Directeur Administratif | - | 01/11/2006 |
Directeur Financier/CFO | - | 01/11/2006 |
Formation de Joseph A. Markey
University of Scranton | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Chief Administrative Officer | 1 |
Director of Finance/CFO | 1 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Valentis, Inc.
![]() Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
- Bourse
- Insiders
- Joseph A. Markey
- Expérience